Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Depreciation and Depletion (2016 - 2022)

Lexaria Bioscience's Depreciation and Depletion history spans 8 years, with the latest figure at $23893.0 for Q2 2022.

  • Quarterly results put Depreciation and Depletion at $23893.0 for Q2 2022, down 14.45% from a year ago — trailing twelve months through May 2022 was $105916.0 (down 5.99% YoY), and the annual figure for FY2021 was $111718.0, down 0.92%.
  • Depreciation and Depletion for Q2 2022 was $23893.0 at Lexaria Bioscience, down from $26163.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $28875.0 in Q3 2020 to a low of $462.0 in Q1 2018.
  • The 5-year median for Depreciation and Depletion is $26853.5 (2019), against an average of $20274.2.
  • The sharpest move saw Depreciation and Depletion soared 4200.95% in 2019, then decreased 14.45% in 2022.
  • Year by year, Depreciation and Depletion stood at $1603.0 in 2018, then skyrocketed by 1616.28% to $27512.0 in 2019, then grew by 1.52% to $27929.0 in 2020, then rose by 0.0% to $27930.0 in 2021, then decreased by 14.45% to $23893.0 in 2022.
  • According to Business Quant data, Depreciation and Depletion over the past three periods came in at $23893.0, $26163.0, and $27930.0 for Q2 2022, Q1 2022, and Q4 2021 respectively.